mdh006

Mark Hurwitz, MD, FACRO

Contact Dr. Hurwitz

111 South 11th Street
Bodine Cancer Center,
Suite G-301
Philadelphia, PA 19107

(215) 955-6644
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Quality assurance guidelines for superficial hyperthermia clinical trials: II. Technical requirements for heating devices | Leitlinien zur Qualit├Ątssicherung der lokalen Hyperthermie in klinischen Studien: II. Technische Anforderungen an Heizger├Ąte
  2. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements
  3. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  4. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  5. Feasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer
  6. Optimization of chest wall hyperthermia treatment using a virtual human chest model
  7. Focused ultrasound for treatment of bone tumours
  8. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data
  9. International consensus on use of focused ultrasound for painful bone metastases: Current status and future directions
  10. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  11. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: Phase III trial results
  12. High dose rate brachytherapy boost for prostate cancer: A systematic review
  13. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  14. Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring
  15. The quality frontier
  16. Hyperthermia, radiation and chemotherapy: The role of heat in multidisciplinary cancer care
  17. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
  18. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  19. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results.
  20. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer